May 18, 2024

Electrocompetent Cells Market is Estimated to Witness High Growth Owing to Increasing Adoption in Synthetic Biology & Gene Cloning Applications

The electrocompetent cells market has witnessed significant growth owing to increasing adoption of gene cloning procedures, recombinant DNA technology in biotechnology and pharmaceutical research. Electrocompetent cells are chemically treated bacterial cells which are capable of taking up foreign plasmid DNA or genes through electroporation. They find wide usage in cloning and expression of recombinant DNA molecules.

The global electrocompetent cells market is estimated to be valued at US$ 2.07 billion in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the electrocompetent cells market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., New England Biolabs, Inc., GenScript Biotech Corporation, Lucigen Corporation, Takara Bio Inc., Delphi Genetics S.A., IBA GmbH, Scarab Genomics LLC, Zymo Research Corporation, Bioline GmbH (Meridian Bioscience), and SelectScience.

The key opportunities in the electrocompetent cells market include growing R&D investment in pharmaceutical and biotech sector. Advancements in cell line development and gene therapy also provide new opportunities for electrocompetent cells.

Technological advancements like automated electroporation systems, new cloning techniques like Gibson Assembly have enhanced efficiency of gene cloning procedures utilizing electrocompetent cells. Developments in CRISPR Cas9 gene editing have further increased adoption of electrocompetent cells in synthetic biology applications.

Market drivers

The primary drivers for electrocompetent cells market include rising incidence of chronic diseases increasing research in genetic disorders and need for biosimilars. Growing focus on precision medicine and personalized therapeutics also augment the demand for electrocompetent cells. Increasing R&D investment by pharmaceutical and biotech players specially in recombinant protein production further propels the market growth.

Current challenges in the Electrocompetent Cells Market
The Electrocompetent Cells market is facing challenges when it comes to maintaining efficient supply chains due to the disruption caused by the COVID-19 pandemic. This has negatively impacted the availability of raw materials and production of competent cells across regions. Furthermore, stringent regulations pertaining to the manufacture and use of genetically modified organisms pose compliance challenges. High costs associated with competent cell production also restrict market growth to some extent. however, growing R&D in the life sciences industry is expected to help overcome some of these hurdles going forward.

SWOT Analysis
Strength: Wide availability of commercial electrocompetent cell strains is a key strength. E. coli remains the preferred host for plasmid transformation due to robust protocols for efficient electrocompetent cell preparation.
Weakness: Requirement of specialist equipment and technical expertise for electrotransformation process. Shelf life stability can also be a concern for some competent cell types.
Opportunity: Growth in recombinant protein production and DNA synthesis market expands the potential customer base. Increasing research in novel expression systems using non-E.coli hosts also presents opportunities.
Threats: Biosafety issues due to accidental release of genetically modified organisms. Switch to alternative transformation methods such as heat shock limits the scope of electrocompetent cells.

While North America dominates the global electrocompetent cells market currently in terms of value, Asia Pacific is emerging as a high growth region. The presence of leading life science research hubs and biopharma companies driving R&D activities in countries like China, India, and South Korea is fueling market growth. Government initiatives to promote bioscience industries also support the regional market.

Europe accounts for the second largest share of the global electrocompetent cells market. Countries such as Germany, United Kingdom, and France have a strong bioscience research infrastructure that generates sizable demand. The growing CTMoT industry further complements market expansion. However, the Asia Pacific region is witnessing the fastest growth and will likely surpass Europe during the forecast period supported by increasing investments, research expansions, and a developing bioscience manufacturing sector across Asian countries.


  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it